{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:33:15Z","timestamp":1794360795300,"version":"4.9.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.eururo.2024.12.002","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T20:28:55Z","timestamp":1735244935000},"page":"536-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["The Financial Burden of Localized and Metastatic Bladder Cancer"],"prefix":"10.1016","volume":"87","author":[{"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.12.002_b0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0010","unstructured":"The International Agency for Research on Cancer (IARC). Global cancer observatory. 2022. https:\/\/gco.iarc.fr\/en."},{"key":"10.1016\/j.eururo.2024.12.002_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0020","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2024.12.002_b0025","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.01.011","article-title":"The cost of cancer in Europe 2018","volume":"129","author":"Hofmarcher","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0035","doi-asserted-by":"crossref","first-page":"39.e11","DOI":"10.1016\/j.urolonc.2019.10.016","article-title":"Longitudinal patterns of cost and utilization of Medicare beneficiaries with bladder cancer","volume":"38","author":"Sloan","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0040","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/tbm\/ibab091","article-title":"Financial toxicity in cancer care: origins, impact, and solutions","volume":"11","author":"Abrams","year":"2021","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.eururo.2024.12.002_b0045","doi-asserted-by":"crossref","first-page":"76.e1","DOI":"10.1016\/j.urolonc.2020.09.030","article-title":"A national cross-sectional survey of financial toxicity among bladder cancer patients","volume":"39","author":"Ehlers","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0050","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00520-019-04975-y","article-title":"Financial toxicity and its associations with health-related quality of life among urologic cancer patients in an upper middle-income country","volume":"28","author":"Ting","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0055","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.12.002_b0060","unstructured":"NHS. 2022. https:\/\/www.nhs.uk."},{"key":"10.1016\/j.eururo.2024.12.002_b0065","unstructured":"AIFA. https:\/\/www.aifa.gov.it."},{"key":"10.1016\/j.eururo.2024.12.002_b0070","unstructured":"Joint Formulary Committee. British National Formulary (BNF 86). 2023."},{"key":"10.1016\/j.eururo.2024.12.002_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.eururo.2024.12.002_b0085","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","article-title":"Risk of bias in model-based economic evaluations: the ECOBIAS checklist","volume":"16","author":"Adarkwah","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.eururo.2024.12.002_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033509","article-title":"Exposure to endocrine-disrupting chemicals and anthropometric measures of obesity: a systematic review and meta-analysis","volume":"10","author":"Ribeiro","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.eururo.2024.12.002_b0095","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.eururo.2024.12.002_b0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.urology.2021.05.008","article-title":"The economics of cystoscopy: a microcost analysis","volume":"157","author":"Kenigsberg","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.12.002_b0105","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1464-410X.2010.10026.x","article-title":"Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity","volume":"108","author":"Kamat","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.12.002_b0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00345-022-04252-4","article-title":"Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis","volume":"41","author":"Hekman","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0115","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.juro.2013.03.117","article-title":"Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma","volume":"190","author":"Gayed","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2022.100326","article-title":"Socio-economic burden of disease: survivorship costs for bladder cancer","volume":"32","author":"Michaeli","year":"2022","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.eururo.2024.12.002_b0125","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0130","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/j.juro.2012.08.005","article-title":"Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases","volume":"188","author":"Lee","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.euros.2021.12.008","article-title":"Trial-based Cost-effectiveness analysis of an immediate postoperative mitomycin C instillation in patients with non\u2013muscle-invasive bladder cancer","volume":"37","author":"Hentschel","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2024.12.002_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non\u2013muscle-invasive bladder cancer among older adults, 2004\u20132013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.12.002_b0145","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JU.0000000000001023","article-title":"Cost-effectiveness of maintenance bacillus Calmette-Gu\u00e9rin for intermediate and high risk nonmuscle invasive bladder cancer","volume":"204","author":"Sharma","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin in the Veterans Affairs Health System","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.12.002_b0155","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s12325-020-01616-3","article-title":"The impact of progression on healthcare resource utilization and costs among patients with high-grade non-muscle invasive bladder cancer after bacillus Calmette-Gu\u00e9rin therapy: a retrospective SEER-Medicare analysis","volume":"38","author":"Yang","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eururo.2024.12.002_b0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/13696998.2023.2189860","article-title":"Evaluating the cost-utility of intravesical bacillus Calmette-Gu\u00e9rin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK","volume":"26","author":"Grabe-Heyne","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.eururo.2024.12.002_b0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.12.002_b0170","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/cncr.28731","article-title":"Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer","volume":"120","author":"Bachir","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0175","first-page":"142","article-title":"Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application?","volume":"52","author":"Burger","year":"2007","journal-title":"A Germany-based cost analysis. Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0180","doi-asserted-by":"crossref","first-page":"207.e9","DOI":"10.1016\/j.urolonc.2022.11.014","article-title":"Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?","volume":"41","author":"Shore","year":"2023","journal-title":"Urol Oncol"},{"issue":"3 Pt B","key":"10.1016\/j.eururo.2024.12.002_b0185","first-page":"E78","article-title":"Cost-effective treatment of low-risk carcinoma not invading bladder muscle","volume":"111","author":"Green","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.12.002_b0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euros.2023.05.003","article-title":"Photodynamic diagnosis-guided transurethral resection of bladder tumour in participants with a first suspected diagnosis of intermediate- or high-risk non\u2013muscle-invasive bladder cancer: cost-effectiveness analysis alongside a randomised controlled trial","volume":"53","author":"Yu","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2024.12.002_b0195","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s00345-020-03587-0","article-title":"Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB","volume":"39","author":"Todenh\u00f6fer","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0200","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.urology.2014.09.041","article-title":"A cost-effectiveness analysis of management of low-risk non\u2013muscle-invasive bladder cancer using office-based fulguration","volume":"85","author":"Al Hussein Al Awamlh","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.12.002_b0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/bju.16269","article-title":"Long\u2010term outcomes and cost savings of office fulguration of papillary Ta low\u2010grade bladder cancer","volume":"133","author":"Vitug","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.12.002_b0210","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bju.16332","article-title":"Cost\u2010effectiveness analysis of different treatment modalities in BCG\u2010unresponsive NMIBC","volume":"134","author":"Rieger","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.12.002_b0215","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0220","doi-asserted-by":"crossref","first-page":"391.e1","DOI":"10.1016\/j.urolonc.2023.04.005","article-title":"Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: a preliminary cost-effectiveness analysis","volume":"41","author":"Bukavina","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0225","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jval.2022.12.005","article-title":"Cost-effectiveness of nadofaragene firadenovec and pembrolizumab in bacillus Calmette-Gu\u00e9rin immunotherapy unresponsive non\u2013muscle invasive bladder cancer","volume":"26","author":"Joshi","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2024.12.002_b0230","first-page":"797","article-title":"The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer","volume":"27","author":"Beinfeld","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.eururo.2024.12.002_b0235","doi-asserted-by":"crossref","unstructured":"Huo J, Chu Y, Chamie K, et al. Increased utilization of positron emission tomography\/computed tomography (PET\/CT) imaging and its economic impact for patients diagnosed with bladder cancer. Clin Genitourin Cancer. In press. https:\/\/doi.org\/10.1016\/j.clgc.2017.07.018.","DOI":"10.1016\/j.clgc.2017.07.018"},{"key":"10.1016\/j.eururo.2024.12.002_b0240","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.urolonc.2014.05.001","article-title":"Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer","volume":"32","author":"Stevenson","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0245","doi-asserted-by":"crossref","first-page":"834.e1","DOI":"10.1016\/j.urolonc.2021.04.032","article-title":"An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer","volume":"39","author":"Montazeri","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0250","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.34502","article-title":"Comparative cost\u2010effectiveness of neoadjuvant chemotherapy regimens for muscle\u2010invasive bladder cancer: results according to VESPER data","volume":"128","author":"Joyce","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0255","doi-asserted-by":"crossref","first-page":"732.e9","DOI":"10.1016\/j.urolonc.2021.03.004","article-title":"Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer","volume":"39","author":"Khaki","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0260","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2017.07.016","article-title":"Variations in the costs of radical cystectomy for bladder cancer in the USA","volume":"73","author":"Leow","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282324","article-title":"Postoperative complications and hospital costs following open radical cystectomy: a retrospective study","volume":"18","author":"Weinberg","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2024.12.002_b0270","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.juro.2012.01.077","article-title":"The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer","volume":"187","author":"Kim","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0275","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/03007995.2020.1758927","article-title":"Cost of cystectomy-related complications in patients with bladder cancer in the United States","volume":"36","author":"Malangone-Monaco","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eururo.2024.12.002_b0280","doi-asserted-by":"crossref","first-page":"932.e9","DOI":"10.1016\/j.urolonc.2020.05.014","article-title":"The cost of obesity in radical cystectomy","volume":"38","author":"Huynh","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0285","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejso.2022.07.023","article-title":"Cost-analysis of robot-assisted radical cystectomy in Europe: a cross-country comparison","volume":"49","author":"Mjaess","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0290","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2024.01.018","article-title":"Robot-assisted radical cystectomy with totally intracorporeal urinary diversion versus open radical cystectomy: 3-year outcomes from a randomised controlled trial","volume":"85","author":"Mastroianni","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0295","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.17255","article-title":"Cost-effectiveness of robot-assisted radical cystectomy vs open radical cystectomy for patients with bladder cancer","volume":"6","author":"Dixon","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.12.002_b0300","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euf.2018.07.001","article-title":"Cost-effectiveness of robot-assisted radical cystectomy using a propensity-matched cohort","volume":"6","author":"Kukreja","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.12.002_b0305","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.euf.2018.04.014","article-title":"A cost-effectiveness modeling study of robot-assisted (RARC) versus open radical cystectomy (ORC) for bladder cancer to inform future research","volume":"5","author":"Michels","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.12.002_b0310","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2017.03.023","article-title":"Does implementing an enhanced recovery after surgery protocol increase hospital charges? Comparisons from a radical cystectomy program at a specialty cancer center","volume":"105","author":"Chipollini","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.12.002_b0315","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euf.2015.06.009","article-title":"Cost analysis of the enhanced recovery after surgery protocol in patients undergoing radical cystectomy for bladder cancer","volume":"2","author":"Nabhani","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.12.002_b0320","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.juro.2013.12.015","article-title":"Alvimopan, a peripherally acting \u03bc-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial","volume":"191","author":"Kauf","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0325","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/UPJ.0000000000000332","article-title":"Naloxegol versus alvimopan for enhancing postoperative recovery following radical cystectomy for bladder cancer","volume":"9","author":"Kirk","year":"2022","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2024.12.002_b0330","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eururo.2024.12.002_b0335","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.4372","article-title":"Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer","volume":"154","author":"Williams","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eururo.2024.12.002_b0340","doi-asserted-by":"crossref","first-page":"273.e1","DOI":"10.1016\/j.urolonc.2022.01.007","article-title":"Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer","volume":"40","author":"Golla","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0345","doi-asserted-by":"crossref","unstructured":"Brodtkorb TH, Knight C, Farzam Kamgar, et al. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. J Med Econ Published online March 12, 2024;27:543\u201353.","DOI":"10.1080\/13696998.2024.2329019"},{"key":"10.1016\/j.eururo.2024.12.002_b0350","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma [published correction appears in N Engl J Med. 2021 Aug 26;385(9):864. doi: 10.1056\/NEJMx210012]","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.002_b0355","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44783","article-title":"Estimated cost of circulating tumor DNA for posttreatment surveillance of human papillomavirus\u2013associated oropharyngeal cancer","volume":"5","author":"Kowalchuk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.12.002_b0360","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40273-021-01047-0","article-title":"Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer","volume":"39","author":"To","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.eururo.2024.12.002_b0365","doi-asserted-by":"crossref","first-page":"3.180.e11","DOI":"10.1016\/j.urolonc.2018.11.016","article-title":"Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States","volume":"37","author":"Criss","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0370","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/13696998.2019.1591424","article-title":"Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma","volume":"22","author":"Aly","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.eururo.2024.12.002_b0375","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/oncolo\/oyad174","article-title":"Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I study)","volume":"28","author":"Bilen","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2024.12.002_b0380","doi-asserted-by":"crossref","unstructured":"Contieri R, Martini A, Mertens LS, et al. The financial burden of guideline-recommended cancer medications for metastatic urothelial carcinoma. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2023.12.002.","DOI":"10.1016\/j.euf.2023.12.002"},{"key":"10.1016\/j.eururo.2024.12.002_b0385","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0490","article-title":"Multinational analysis of estimated health care costs related to extended-interval fixed dosing of checkpoint inhibitors","volume":"6","author":"Goldstein","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.12.002_b0390","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clgc.2022.10.001","article-title":"Avelumab maintenance treatment after first-line chemotherapy in advanced urothelial carcinoma\u2013a cost-effectiveness analysis","volume":"21","author":"Lin","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0395","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1007\/s12325-021-01950-0","article-title":"Cost-effectiveness of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in the United States","volume":"38","author":"Peng","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eururo.2024.12.002_b0400","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.eururo.2018.03.006","article-title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer","volume":"74","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0405","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.euo.2018.09.012","article-title":"Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in Sweden","volume":"3","author":"Srivastava","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0410","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/13696998.2020.1770261","article-title":"The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States","volume":"23","author":"Slater","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.eururo.2024.12.002_b0415","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.3747\/co.27.5459","article-title":"A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer","volume":"27","author":"Parmar","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.eururo.2024.12.002_b0420","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bju.16003","article-title":"Financial toxicity from newly approved second-\/third-line agents in metastatic urothelial carcinoma","volume":"131","author":"Benjamin","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.12.002_b0425","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.3390\/cancers13235977","article-title":"The cost of enfortumab vedotin wastage due to vial size\u2014a real-world analysis","volume":"13","author":"Sarfaty","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.12.002_b0430","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.12.002_b0435","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.1016\/j.clgc.2018.03.002","article-title":"Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy","volume":"16","author":"Flannery","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0440","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.juro.2017.10.049","article-title":"Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life","volume":"199","author":"Casilla-Lennon","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.12.002_b0445","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2023.04.040","article-title":"Evaluating financial toxicity in urologic practice","volume":"179","author":"Glazyrine","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.12.002_b0450","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/BLC-211615","article-title":"Quality of life and health state utilities in bladder cancer","volume":"8","author":"Smith","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0455","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00520-024-08357-x","article-title":"Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program","volume":"32","author":"Parikh","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2024.12.002_b0460","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7116","article-title":"Association of household net worth with healthcare costs after radical cystectomy using real\u2010world data","volume":"13","author":"Washington","year":"2024","journal-title":"Cancer Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824027441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824027441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:31:43Z","timestamp":1744651903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824027441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0302283824027441"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.12.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Financial Burden of Localized and Metastatic Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}